[1]
|
A. E. Frost, D. B. Badesch, R. J. Barst, R. L. Benza, C. G. Elliott, H. W. Farber, et al., “The Changing Picture of Patients with Pulmonary Arterial Hypertension in the United States: How REVEAL Differs from Historic and Non-US Contemporary Registries,” Chest, Vol. 139, No. 1, 2011, pp. 128-137. doi:10.1378/chest.10-0075
|
[2]
|
G. E. D’Alonzo, R. J. Barst, S. M. Ayres, E. H. Bergofsky, B. H. Brundage, K. M. Detre, et al., “Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry,” Annals of Internal Medicine, Vol. 115, No. 5, 1991, pp. 343-349.
|
[3]
|
V. Pengo, A. W. Lensing, M. H. Prins, A. Marchiori, B. L. Davidson, F. Tiozzo, et al., “Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism,” The New England Journal of Medicine, Vol. 350, No. 22, 2004, pp. 2257-2264.
doi:10.1056/NEJMoa032274
|
[4]
|
D. Poli, E. Grifoni, E. Antonucci, C. Arcangeli, D. Prisco, R. Abbate, et al., “Incidence of Recurrent Venous Thromboembolism and of Chronic Thromboembolic Pulmonary Hypertension in Patients after a First Episode of Pulmonary Embolism,” Journal of Thrombosis Thrombolysis, Vol. 30, No. 3, 2010, pp. 294-299.
doi:10.1007/s11239-010-0452-x
|
[5]
|
C. Becattini, G. Agnelli, R. Pesavento, M. Silingardi, R. Poggio, M. R. Taliani, et al., “Incidence of Chronic Thromboembolic Pulmonary Hypertension after a First Episode of Pulmonary Embolism,” Chest, Vol. 130, No. 1, 2006, pp. 172-175. doi:10.1378/chest.130.1.172
|
[6]
|
D. B. Badesch, H. C. Champion, M. A. Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, et al., “Diagnosis and Assessment of Pulmonary Arterial Hypertension,” Journal of the American College of Cardiology, Vol. 54, No. 1, 2009, pp. S55-S66. doi:10.1016/j.jacc.2009.04.011
|
[7]
|
O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, et al., “Long-Term Intravenous Epoprostenol Infusion in Primary Pulmonary Hypertension: Prognostic Factors and Survival,” Journal of the American College of Cardiology, Vol. 40, No. 4, 2002, pp. 780-788.
doi:10.1016/S0735-1097(02)02012-0
|
[8]
|
V. V. McLaughlin, A. Shillington and S. Rich. “Clinical Investigation and Reports Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy,” Circulation, Vol. 106, No. 12, 2002, pp. 1477-1482.
doi:10.1161/01.CIR.0000029100.82385.58
|
[9]
|
N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, et al., “Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension,” European Respiratory Journal, Vol. 34, No. 6, 2009, pp. 1219-1263. doi:10.1183/09031936.00139009
|
[10]
|
N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani and A. Branzi, “A Meta-Analysis of Randomized Controlled Trials in Pulmonary Arterial Hypertension,” European Heart Journal, Vol. 30, No. 4, 2009, pp. 394-403. doi:10.1093/eurheartj/ehp022
|
[11]
|
A. Macchia, R. Marchioli, G. Tognoni, M. Scarano, R. Marfisi, L. Tavazzi, et al., “Systematic Review of Trials Using Vasodilators in Pulmonary Arterial Hypertension: Why a New Approach Is Needed,” American Heart Journal, Vol. 159, No. 2, 2010, pp. 245-257.
doi:10.1016/j.ahj.2009.11.028
|
[12]
|
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, et al., “Prognosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines,” Chest, Vol. 126, No. 1, 2004, pp. 78S-92S. doi:10.1378/chest.126.1_suppl.78S
|
[13]
|
S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky and S. E. Kimmel, “Hemodynamics and Survival in Patients with Pulmonary Arterial Hypertension Related to Systemic Sclerosis,” Chest, Vol. 123, No. 2, 2003, pp. 344-350. doi:10.1378/chest.123.2.344
|
[14]
|
V. McLaughlin, M. Humbert, G. Coghlan, P. Nash and V. Steen, “Pulmonary Arterial Hypertension: The Most Devastating Vascular Complication of Systemic Sclerosis,” Rheumatology, Vol. 48, No. 3, 2009, pp. iii25-iii31.
doi:10.1093/rheumatology/kep107
|
[15]
|
S. C. Mathai, L. K. Hummers, H. C. Champion, F. M. Wigley, A. Zaiman, P. M. Hassoun, et al., “Survival in Pulmonary Hypertension Associated with the Scleroderma Spectrum of Diseases: Impact of Interstitial Lung Disease,” Arthritis and Rheumatism, Vol. 60, No. 2, 2009, pp. 569-577. doi:10.1002/art.24267
|
[16]
|
S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki, M. Fujita, et al., “Clinical Correlates and Prognostic Significance of Six-Minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing,” American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 2, 2000, pp. 487-492.
|
[17]
|
P. E. Subias, M. J. Cano and A. Flox, “Medical Treatment in Patients with Chronic Thromboembolic Pulmonary Hypertension,” Archivos De Bronconeumologia, Vol. 45. No. 6, 2009, pp. 35-39.
|
[18]
|
X. Jais, A. M. D’Armini, P. Jansa, A. Torbicki, M. Delcroix, H. A. Ghofrani, et al., “Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of ChronIc Thromboembolic Pulmonary Hypertension), a Randomized, Placebo-controlled Trial,” Journal of the American College of Cardiology, Vol. 52, No. 25, 2008, pp. 2127-2134.
|
[19]
|
H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, et al., “Inhaled Iloprost for Severe Pulmonary Hypertension,” The New England Journal of Medicine, Vol. 347, No. 5, 2002, pp. 322-329.
doi:10.1056/NEJMoa020204
|